The risk of venous thromboembolism in atopic dermatitis: a population-based cohort study
British Journal of Dermatology · 2026
DOI: 10.1093/bjd/ljaf418 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Lina U Ivert und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology and Venereology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Venous Thromboembolism, Dermatitis, Atopic. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a common inflammatory skin disease. Evidence on baseline venous thromboembolism (VTE) risk is inconsistent, but a clear understanding of this risk may be crucial in disease management.
Objectives
To evaluate whether individuals with AD have a higher risk of incident VTE than the general population and to assess variations in risk by demographics and disease severity.
Methods
This nationwide matched cohort study used Swedish health and population registers to examine VTE incidence in patients with AD. The study population included individuals diagnosed with AD who were aged ≥ 18 years from 1 January 2007. Patients with AD were matched by birth year and sex with up to five controls who did not have AD. AD severity was defined by use of systemic immunomodulatory treatment or hospitalization with AD as the primary diagnosis. Incidence rates per 1000 person-years were calculated for the AD cohort and the general population. Cox proportional hazard regressions were used to estimate VTE hazard ratios, adjusted for comorbidities, treatments and socioeconomic variables. Follow-up started at first AD diagnosis or 18th birthday and ended at first VTE event, emigration, death or end of study (31 December 2023).
Results
We identified 210 492 individuals with AD. These individuals were matched with 1 048 395 controls without AD. At inclusion, 94.1% had nonsevere AD and 5.9% had severe AD. The AD cohort had 3292 VTE events, with an incidence rate of 1.49 per 1000 person-years, compared with 1.71 per 1000 person-years in the general population. VTE risk was similar in individuals with AD and the general population [adjusted hazard ratio (aHR) 1.04, 95% confidence interval (CI) 1.01–1.09]. Those with severe AD had a higher VTE risk than the general population (aHR 1.93, 95% CI 1.70–2.14). Elevated VTE risk in severe AD was seen across all age groups. The youngest group (18–39 years) exhibited a higher relative risk than age-matched controls (aHR 2.95, 95% CI 2.40–3.59).
Conclusions
This large population-based study found similar overall VTE risk between patients with AD and the general population, but higher risk in those with severe AD, particularly among younger adults. Further research is needed to clarify the clinical implications of these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Dermatology and Venereology, Karolinska Institutet, Stockholm, Sweden.
- Center for Occupational and Environmental Medicine, Stockholm Region, Stockholm, Sweden.
- Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.
Zitieren
APA
Ivert, L. U., Anveden-Berglind, I., Gembert, K., Eriksson, J., Hernan Giunta, D., Hägg, D., & Linder, M. (2026). The risk of venous thromboembolism in atopic dermatitis: a population-based cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf418
Vancouver
Ivert LU, Anveden-Berglind I, Gembert K, Eriksson J, Hernan Giunta D, Hägg D, et al. The risk of venous thromboembolism in atopic dermatitis: a population-based cohort study. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljaf418
BibTeX
@article{Ivert2026,
author = {Ivert, Lina U and Anveden-Berglind, Ina and Gembert, Karin and Eriksson, Julia and Hernan Giunta, Diego and Hägg, David and Linder, Marie},
title = {The risk of venous thromboembolism in atopic dermatitis: a population-based cohort study},
journal = {British Journal of Dermatology},
year = {2026},
doi = {10.1093/bjd/ljaf418}
}
EUVIMED